GW&K Investment Management Trims Neurocrine Biosciences Stake

Institutional investor reduces position in biotech company by 2.9%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

GW&K Investment Management LLC lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 594,385 shares of the company's stock after selling 17,980 shares during the quarter.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. Institutional investors closely monitor their holdings in such companies, as changes in ownership can signal shifts in market sentiment or strategic priorities.

The details

GW&K Investment Management LLC reduced its stake in Neurocrine Biosciences by selling 17,980 shares during the third quarter. The firm now owns approximately 594,385 shares, or 0.60% of the company's outstanding stock, valued at $83.44 million as of the end of the reporting period.

  • GW&K Investment Management LLC lowered its position in Neurocrine Biosciences shares during the third quarter of 2026.

The players

GW&K Investment Management LLC

An institutional investment management firm that previously owned a 0.60% stake in Neurocrine Biosciences.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in GW&K Investment Management's position in Neurocrine Biosciences, while relatively small, could signal a shift in investor sentiment or portfolio strategy for the institutional investor. However, the company remains a significant shareholder, underscoring the continued importance of Neurocrine Biosciences in GW&K's investment portfolio.